Tags

Type your tag names separated by a space and hit enter

Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study.
Eur Urol. 2005 Apr; 47(4):530-5; discussion 535-6.EU

Abstract

PURPOSE

The aim of this study was to investigate the effect of potassium paraaminobenzoate (Potaba) in Peyronie's disease in a prospective, randomized, double-blind, placebo-controlled, multicentre study during a 12-months period of treatment.

PATIENTS AND METHODS

103 patients with Peyronie's disease and a history <12 months, non-calcified plaques and without pre-treatment were included. 51 were randomized to potassium paraaminobenzoate, 52 to placebo receiving 4 x 3g/day for 12 months. Follow-up was performed during the treatment period. Response has been defined as regression in plaque-size and/or reduction in penile curvature of at least 30%. Data analysis was focussed on 75 patients who completed the study [valid-cases (VC)].

RESULTS

No severe adverse events occurred. Response rates were 74.3% on potassium paraaminobenzoate and 50.0% on placebo (p=0.016). Mean plaque-size decreased from 259 mm(2) to 142 mm(2) in the treatment arm. In the placebo group, plaque-size aggravated from 259 mm(2) to 303 mm(2) after 6 months but improved slightly to 233 mm(2) after 12 months. Differences between the groups were significant (p=0.042). Pre-existing curvature did not improve under the drug (p=0.066) but comparing the development of new curvature or deterioration of pre-existing curvature under potassium paraaminobenzoate penile deviation remained stable. However, under placebo penile curvature deteriorated significantly in 32.5% of the cases (p<0.001). No significant differences concerning decrease of pain could be observed between the two groups (82.6% vs. 77.3%).

CONCLUSIONS

The results of this study indicate a significant plaque-related effect of potassium paraaminobenzoate. There was no relevant difference with regard to improvement of pre-existing penile deviation. However, under potassium paraaminobenzoate a significant protective effect on deterioration of penile curvature could be demonstrated. Potassium paraaminobenzoate appears to be useful to stabilize the disorder and prevent progression of penile curvature.

Authors+Show Affiliations

Department of Urology and Pediatric Urology Rudolf-Buchheim-Str. 7 D-35385 Giessen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15774254

Citation

Weidner, Wolfgang, et al. "Potassium Paraaminobenzoate (POTABA) in the Treatment of Peyronie's Disease: a Prospective, Placebo-controlled, Randomized Study." European Urology, vol. 47, no. 4, 2005, pp. 530-5; discussion 535-6.
Weidner W, Hauck EW, Schnitker J, et al. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530-5; discussion 535-6.
Weidner, W., Hauck, E. W., & Schnitker, J. (2005). Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. European Urology, 47(4), 530-5; discussion 535-6.
Weidner W, et al. Potassium Paraaminobenzoate (POTABA) in the Treatment of Peyronie's Disease: a Prospective, Placebo-controlled, Randomized Study. Eur Urol. 2005;47(4):530-5; discussion 535-6. PubMed PMID: 15774254.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. AU - Weidner,Wolfgang, AU - Hauck,Ekkehard W, AU - Schnitker,Jörg, AU - ,, Y1 - 2005/01/13/ PY - 2004/10/13/received PY - 2004/12/28/accepted PY - 2005/3/19/pubmed PY - 2005/9/24/medline PY - 2005/3/19/entrez SP - 530-5; discussion 535-6 JF - European urology JO - Eur Urol VL - 47 IS - 4 N2 - PURPOSE: The aim of this study was to investigate the effect of potassium paraaminobenzoate (Potaba) in Peyronie's disease in a prospective, randomized, double-blind, placebo-controlled, multicentre study during a 12-months period of treatment. PATIENTS AND METHODS: 103 patients with Peyronie's disease and a history <12 months, non-calcified plaques and without pre-treatment were included. 51 were randomized to potassium paraaminobenzoate, 52 to placebo receiving 4 x 3g/day for 12 months. Follow-up was performed during the treatment period. Response has been defined as regression in plaque-size and/or reduction in penile curvature of at least 30%. Data analysis was focussed on 75 patients who completed the study [valid-cases (VC)]. RESULTS: No severe adverse events occurred. Response rates were 74.3% on potassium paraaminobenzoate and 50.0% on placebo (p=0.016). Mean plaque-size decreased from 259 mm(2) to 142 mm(2) in the treatment arm. In the placebo group, plaque-size aggravated from 259 mm(2) to 303 mm(2) after 6 months but improved slightly to 233 mm(2) after 12 months. Differences between the groups were significant (p=0.042). Pre-existing curvature did not improve under the drug (p=0.066) but comparing the development of new curvature or deterioration of pre-existing curvature under potassium paraaminobenzoate penile deviation remained stable. However, under placebo penile curvature deteriorated significantly in 32.5% of the cases (p<0.001). No significant differences concerning decrease of pain could be observed between the two groups (82.6% vs. 77.3%). CONCLUSIONS: The results of this study indicate a significant plaque-related effect of potassium paraaminobenzoate. There was no relevant difference with regard to improvement of pre-existing penile deviation. However, under potassium paraaminobenzoate a significant protective effect on deterioration of penile curvature could be demonstrated. Potassium paraaminobenzoate appears to be useful to stabilize the disorder and prevent progression of penile curvature. SN - 0302-2838 UR - https://wwww.unboundmedicine.com/medline/citation/15774254/Potassium_paraaminobenzoate__POTABA__in_the_treatment_of_Peyronie's_disease:_a_prospective_placebo_controlled_randomized_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(05)00002-3 DB - PRIME DP - Unbound Medicine ER -